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Abstract
BACKGROUND—Information on the effects of different pharmaceuticals on fertility is sparse. 
Human and animal models indicate that antidepressant use could have a negative effect on fertility 
through alteration of levels of the neurosteroid, allopregnanolone.
OBJECTIVE—The objective of this study is to assess the effects of antidepressants on the natural 
fertility in women.
STUDY DESIGN—A secondary analysis of data from Time to Conceive, a prospective cohort 
study, was conducted. Women aged 30-44 without history of infertility, early in their attempts to 
conceive, were followed with standardized pregnancy testing until pregnancy was detected. 
Medication use was assessed at enrollment, daily for up to four months, and then monthly. For this 
analysis, discrete time regression models were created to calculate the association between 
antidepressant use and fecundability. Potential confounders: age, body mass index, caffeine, 
alcohol use, and education were included in all models.
RESULTS—Ninety-two (9.6%) of 957 women reported antidepressant use while attempting to 
conceive. Women taking antidepressants were more likely to be non-Hispanic Caucasian (91% vs. 
75%, p<0.01) and to consume alcoholic beverages (74% vs. 61%, p<0.01). Antidepressant use at 
enrollment had an adjusted FR of 0.86 (95% CI: 0.63-1.20). However, time varying analyses 
suggested that antidepressant use in a given cycle is associated with a reduced probability of 
conceiving in that cycle (adjusted FR 0.75 95% CI: 0.53-1.06). After adjusting for history of 
depression or restricting the analysis to women who reported a history of depression, the 
association between antidepressant use and decreased fecundability remained [adjusted FR 0.66 
(95% CI 0.45-0.97) and (adjusted FR 0.64, 95% CI: 0.43-0.94), respectively].
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CONCLUSION—Our data suggest that antidepressants may reduce the probability of a woman 
with a history of depression to conceive naturally. Future studies are needed to differentiate the 
extent to which this association is due to the antidepressant itself versus the underlying depression.
Keywords
Antidepressants; depression; fertility; fecundability
INTRODUCTION
Antidepressants are the first line of treatment for unipolar major depression1 and a number 
of other mood disorders, like obsessive compulsive disorder.2 In 2011, antidepressants were 
the most dispensed drug in the United States accounting for over 260 million prescriptions.3 
Antidepressants were disproportionately used by women,4 the majority of reproductive age, 
compared to men.5 Although there has been significant research on the teratogenicity of 
antidepressants, little is known about their direct impact on fertility.
The three most commonly prescribed classes of antidepressants increase allopregnanolone,6 
a progesterone derivative considered a neurosteroid that is produced and is neuroactive in the 
brain. Allopregnanolone is a positive allosteric modulator of the gamma aminobutyric acid 
(GABAA) receptor. Its presence enhances the activity of GABA, which is the main 
inhibitory neurotransmitter in the central nervous system, including the hypothalamus.
Research on rodents suggest that an antidepressant-induced increase in allopregnanolone 
levels could lead to dysregulation of the hypothalamic-pituitary-ovarian (HPO) axis. 
Incubation of hypothalamic tissue with allopregnanolone suppresses GnRH release in a 
concentration-dependent manner. The effects are blocked with the addition of a GABA-
antagonist, suggesting that allopregnanolone increases GABA activity, suppressing GnRH 
release.7 Accordingly, injection of allopregnanolone into the hypothalamus of rats has been 
shown to decrease circulating LH levels and result in fewer oocytes at oestrus.6 The results 
of animal models have been consistent in humans. Intravenous administration of 
allopregnanolone in healthy, fertile women decreases follicle stimulating hormone (FSH) 
and LH levels8 and subsequently decreases rates of ovulation. This dysregulation in 
allopregnanolone could inhibit the pulsatile action of GnRH needed to sustain proper 
synchronization of ovulation, resulting in infertility.
The above evidence suggests that antidepressants may contribute to changes in the HPO axis 
through their GABAergic action. HPO axis dysfunction can manifest in numerous ways, 
including anovulation or luteal phase defects, which can negatively impact a woman’s 
ability to conceive. We hypothesized that antidepressant use would impair natural fertility, 
which we examined by analyzing the effect of antidepressants on fecundability, the 
probability of conceiving in a menstrual cycle.
MATERIALS AND METHODS
This study is a secondary analysis of Time to Conceive (TTC), an ongoing prospective time-
to-pregnancy cohort study approved by the institutional review board at the University of 
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North Carolina. A detailed description of the TTC study has been published previously.9 In 
brief, women were recruited to the study via community-based fliers, informational emails, 
internet, radio, television and print advertising, and community blogs. English-speaking 
women 30 to 44 years old, who had been attempting to conceive for less than three months, 
were eligible to participate. Women with a history of infertility, polycystic ovary syndrome, 
pelvic inflammatory disease, endometriosis, pelvic radiation, or a partner with a history of 
infertility were excluded. Our analysis includes women enrolled between April 2008 and 
July 2015. Information was collected via a web-based questionnaires and daily diaries. At 
enrollment women provided demographic information, medical and surgical history, 
obstetric, gynecologic, and menstrual history, information on behaviors, height and weight, 
and pregnancy history, as well as partner demographics. Women were asked if they had a 
history of anxiety or depression (yes/no). The question was not restricted to any specific type 
of depression or anxiety. The Cerner Multum drug database system was embedded to 
identify and record over-the-counter and prescription medication use. This comprehensive 
database included dosing information and drug names, both generic and brand names.
While attempting to conceive, women completed an online daily diary for four months or 
until pregnancy was detected. The daily diary collected information on vaginal bleeding, 
intercourse, pregnancy test results, and medication use. If the woman did not conceive in the 
first four months of enrollment, she completed an online questionnaire monthly thereafter, 
which also collected information on medication use. The women were followed for twelve 
months or until pregnancy was achieved. Pregnancy tests (sensitivity =20 mIU hCG/mL) 
were provided with standardized instructions. For this analysis, a positive pregnancy test was 
our primary outcome of interest.
Antidepressants were categorized by class via mechanism of action. A comprehensive list of 
traditional antidepressants was constructed. Our list included selective serotonin reuptake 
inhibitors (SSRIs), serotonin/norepinephrine reuptake inhibitors, serotonin antagonist and 
reuptake inhibitors, norepinephrine reuptake inhibitors, norepinephrine/dopamine reuptake 
inhibitors, tri and tetracyclic antidepressants (TCAs), monoamine oxidase inhibitors, and 
other antidepressants. Adjunct antidepressants and other psychotropic medications with 
antidepressant action were excluded.
Statistical Analysis
Women were categorized by antidepressant use (yes/no). Antidepressant use was categorized 
by 1) use at enrollment, 2) use at any given time during the study, and 3) use in a given 
menstrual cycle. Bivariate analyses, using chi-square tests, were used to compare 
demographics and potential covariates (age, race, education level, pregnancy history, 
menstrual cycle regularity and length, previous contraceptive use, body mass index [BMI], 
partner age, smoking status, alcohol use, and caffeine use) between the antidepressant users 
(at any given time in the study) and non-users.
Discrete-time survival models were constructed to assess the relationship between 1) 
antidepressant use at enrollment and fecundability and, as antidepressant use of an 
individual woman could vary over time, 2) antidepressant use in a given cycle and 
fecundability in that given cycle. All analyses were restricted to the first nine cycles of 
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attempt, due to few women remaining after that time. All models accounted for both the 
right censoring and left truncation (due to women enrolling in cycles 1, 2, 3, or 4 of their 
pregnancy attempt) present in the data. In these models, a fecundability ratio (FR) less than 
1.0 suggested reduced fecundability.
In all adjusted models we included both the covariates strongly associated with fecundability 
or antidepressants and those identified in multiple prior studies as related to fecundability. 
These covariates were age, Caucasian race (yes/no), body mass index, education level, and 
alcohol use (yes/no). Maternal age was collapsed into three categories (30–34, 35–37, and 
38–44 years of age), and BMI was categorized into four groups (≤18.4, 18.5-24.9, 25.0–
29.9, and ≥30 kg/m2). Additional analyses adjusted for history of anxiety/depression as 
reported in the baseline questionnaire and restricted analysis to those women, who reported 
a history of anxiety/depression. In an attempt to explore the extent to which underlying 
anxiety/depression may play a role in the relationship between antidepressants and fertility, 
we analyzed the relationship between history of anxiety/depression, as reported in the 
baseline questionnaire and fecundability.
RESULTS
A total of 957 women and 3,355 menstrual cycles were included in this analysis. Of the 
analysis cohort, 70% of women were 30-34 years old, 18% were 35–37 years old, and 12% 
were 38-44 years old. Participants tended to be Caucasian (76%), highly educated (72% with 
some graduate education or more), and normal weight (62%). Six hundred twenty-two 
(65%) of subjects conceived during their first nine cycles of attempt. Analysis was restricted 
to the first nine cycles due to high levels of drop-out past this point.
Ninety-two (9.6%) women reported antidepressant use at some point during enrollment. 
Antidepressant use was reported by 7.6% of women in the first cycle of attempt, 9.0% in the 
second, 8.9% in the third, 8.2% in the sixth, and 11.0% in the eighth. The most frequently 
used antidepressants were SSRIs and all antidepressants, except one report of TCAs, were 
reuptake inhibitors. Women taking antidepressants were more likely to be non-Hispanic 
Caucasian (91% vs. 75%, p<0.01) and to consume alcoholic beverages (74% vs. 61%, 
p<0.01). There were no differences in other variables analyzed (Table 1). Menstrual cycle 
length and history of regular menstrual cycles did not differ at baseline by antidepressant 
use. Antidepressant users at enrollment reported on average 2.18 [standard deviation (SD) 
1.25] acts of intercourse per week, which did not differ significantly from non-users at that 
time with 2.38 (SD 1.59) act per weeks, p= 0.27. Women reporting a history of depression 
had similar fecundability to those who did not (adjusted FR 1.03, 95% CI: 0.82-1.24).
Initial models suggested minimal to no effect of antidepressants on fecundability (Figure 1) 
when analyzing baseline antidepressant use; women who were taking antidepressants at 
enrollment had an adjusted FR of 0.86 (95% CI: 0.63-1.20). When analyzing cycles 
individually, time varying analyses suggested that antidepressant use in a given cycle was 
associated with a reduced probability of conceiving in that cycle (adjusted FR 0.75 95% CI: 
0.53-1.06). After adjusting for a history of anxiety/depression as reported on the baseline 
questionnaire, the association between antidepressant use and fecundability remained 
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[adjusted FR 0.66 (95% CI 0.45-0.97)]. When the analyses were restricted to women with a 
history of anxiety/depression, the association also remained (adjusted FR 0.64, 95% CI: 
0.43-0.94).
DISCUSSION
In this prospective cohort study we found that 9.6% of women took antidepressants while 
trying to conceive. Almost all antidepressants used in our study were reuptake inhibitors, 
sharing a similar mechanism of action. Women in our study who took antidepressants tended 
to be non-Hispanic Caucasian and more likely to consume alcoholic beverages. History of 
depression or anxiety was not associated with fecundability. Antidepressant use within a 
given menstrual cycle was associated with a lower probability of conceiving among women, 
who reported a history of anxiety or depression.
Antidepressant use in our cohort was similar to that in previous studies. A cross sectional 
study of 12,637 Americans found antidepressant use in women aged 18-39 to be 9.2%.4 
Another study found similar rates of antidepressant use in this age group at 9.9%.10 In 
addition, a study of antidepressant use during pre-conception and early pregnancy reported a 
rate of 10.0% and was similar in regards to age and race.11 Retrospective studies relying on 
reported antidepressant use in IVF recipients reported significantly lower rates than 
prospective studies.11–14
Prior studies reported higher rates of antidepressant use in older women and women of 
Caucasian race.4,10 In our study antidepressant users did not differ from non-users by race or 
age. The age distribution did not significantly differ by antidepressant use. Regarding race 
distribution, 79% of antidepressant users were Non-Hispanic Caucasian, while 76% of non-
users were non-Hispanic Caucasian. Our inability to detect previously observed associations 
may be due to the relatively narrow age range and underrepresentation of minorities in this 
study.
We did not find any differences in the reported regularity or length of menstrual cycles 
between women using and not using antidepressants. If menstrual cycle characteristics had 
been different between groups, this may have suggested HPO axis dysfunction. However, 
menstrual cycles tend to be highly variable15 and a lack of these findings does not exclude 
the possibility of HPO axis dysregulation leading to anovulation or luteal phase defects.
Our study found lower fecundability in cycles in which a woman took an antidepressant. 
This finding was statistically significant after adjusting for history of anxiety or depression 
or restricting the analysis to those that reported a history of anxiety or depression. To our 
knowledge, this is the first prospective study to look at the effect of antidepressants on 
fertility. In a case control study, Grodstein et al. found that women who took antidepressants 
for more than six months had 2.9 times the odds of infertility (95% CI 0.9-8.3). This finding 
was based on five cases who took antidepressants.19 Klock et al. performed a retrospective 
study to analyze the effect of SSRIs on the success of IVF treatments, reporting that the 
group of women using SSRIs had a lower pregnancy rate than non-users (40% vs. 51%). 
Their findings were limited by a small sample size and were not statistically significant.12
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The observed association between antidepressants and fecundability could be due to the 
antidepressants itself or the underlying fertility. This study was not designed to look at the 
relationship between depression and fecundability. There was a single question on the 
enrollment questionnaire that queried about history of underlying depression or anxiety. This 
simple measure was not associated with fecundability. However, we are unable to determine 
the extent to which antidepressants users or non-users suffered from depression or residual 
depressive symptoms. Therefore, this study is unable to truly differentiate the effect of the 
underlying depression from the antidepressant. Future studies could use validated 
questionnaires to assess anxiety and depression symptoms.
The true relationship between depression and fertility is unknown. Odegard found in a study 
of 30,438 married or previously married women in Norway hospitalized for psychiatric 
disorders, that women with affective psychoses had a similar number of observed children as 
expected for the general population.16 This study assessed severe psychiatric conditions and 
didn’t specifically stratify the differences in mood disorders alone. Harlow et al found, in a 
prospective cohort of women going through menopause, that women with a history of 
depression reported fewer live births.17 Neither of these studies account for desires to 
conceive. In a prospective time-to-pregnancy study, Lynch et al. used the Hospital Anxiety 
and Depression Scale to assess the association between depression and fecundability. They 
did not find an association between depression scores and fecundability. However, 
depression scores for their cohort were within the normal range; thus they were not able to 
assess the impact of depressive disorders.18
Confounding by indication, in which a disease is associated with the use of a medication and 
the outcome, is a problem in may many pharmacological studies.20 A recent study by 
Andersen et al. examined the relationship between antidepressant use and miscarriage using 
a pharmacy database.21 The authors found an increased risk of miscarriage in those women 
taking antidepressants during the first trimester (1.27 HR; 95% CI 1.22-1.33) compared to 
women that did not. However, they found a similarly increased risk of miscarriage in those 
women that stopped the antidepressant prior to conceiving (1.24 HR, 95% CI 1.18-1.30).21 
This would suggest a potential for confounding by indication with this class of medication. 
To try to account for the possibility of confounding by indication, we restricted our analysis 
to women who reported a history of anxiety/depression. However, we did not account for 
current disease or severity of disease. Future studies may need to collect more information to 
allow the use of propensity scores (to predict probability of using antidepressants) in 
analyses.
Our study is not without limitations. By design it includes older reproductive-aged women. 
While this increases the prevalence of antidepressant use, it may decrease generalizability. 
Although we identified numerous variables known to affect both depression and fertility, the 
nature of an observational study precludes us from adjusting for all possible confounders. 
The outcome we used was an epidemiological measure of fecundability, not incidence of 
infertility, and the outcome was pregnancy, not live birth. One would presume, however, that 
decreased fecundability would result in increased rates of infertility. Because our study was 
not originally designed to assess depression, we relied on a self-report of a history of 
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depression/anxiety. As discussed above, this study cannot differentiate between active or 
past depression nor between anxiety and depression.
Our study design was the most important strength of our study. A prospective cohort 
provides the strongest evidence when assessing pharmaceuticals on women attempting to 
conceive, as randomized controlled trials are not done in this context.20 Cross-sectional 
studies are limited by their inability to determine temporal causality. The online self-
reported daily diaries allowed for accuracy, as well as privacy, compared to face-to-face 
interviews, which may be especially important when assessing sensitive information.22 To 
further improve accuracy by avoiding misclassification and monitoring adherence of 
antidepressants, the Center Multum drug database was used.
In conclusion, antidepressants are among the most widely used medications in reproductive-
aged women in the United States. Our study suggests that antidepressant use in women with 
a history of anxiety or depression diminishes natural fertility. While this is concerning, it is 
possible that the indication for the antidepressant is the causal factor. Thus, this study alone 
cannot be used as justification for women to stop their antidepressants when attempting to 
conceive.
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Figure 1. 
Unadjusted Kaplan-Meier Curves of time to pregnancy, according to baseline antidepressant 
use.
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Table 1
Baseline Characteristics of Women taking Antidepressants.
Antidepressant taken
during study
Characteristic Category
No (%)
N=865
Yes (%)
N=92 p
Age (years) 30- 34 611 (70) 64 (69) 0.46
35 to 37 157 (18) 14 (15)
38 and over 97 (11) 14 (15)
Race Non-Hispanic
Caucasian
652 (75) 84 (91) <.01
Other 213 (25) 8 (8)
Education level Less than college
degree
71 (8) 5 (5) 0.77
College degree 174 (20) 17 (18)
Some
graduate/masters
79 (9) 11 (12)
Completed
postgraduate
541 (63) 59 (64)
Nulligravid Previous
pregnancy
445 (51) 53 (58) 0.26
Never been
pregnant
420 (49) 30 (42)
Regular Menstrual Cycles No 122 (14) 13 (14) 1.00
Yes 742 (86) 79 (86)
Body Mass Index (kg/m^2) less than 18.5 23 (3) 1 (1) 0.50
18.5 to 24.9 538 (62) 54 (59)
25 to 29.9 175 (20) 24 (26)
30 and over 128 (15) 13 (14)
Current Smoker No 852 (99) 91 (99) 0.75
Yes 13 (1) 1 (1)
Partner age (years) <50 853 (99) 92 (100) 0.28
50 or more 11 (1) 0 (0)
Past Year Hormonal
contraceptive use
No 474 (55) 44 (48) 0.20
Yes 391 (45) 48 (52)
Caffeinated Beverage
Consumption
No 163 (19) 15 (16) 0.04
Yes 701 (81) 77 (84)
Alcohol Consumption No 335 (39) 24 (26) 0.01
Yes 526 (61) 67 (74)
Average Menstrual Cycle
Length
25 or fewer days 75 (9) 12 (13) 0.28
26-30 days 618 (72) 61 (67)
30-35 days 126 (15) 16 (18)
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Antidepressant taken
during study
Characteristic Category
No (%)
N=865
Yes (%)
N=92 p
36 or more days 42 (5) 2 (2)
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